Skip to main content

Table 1 The detailed information of AS patients

From: IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis

Parameter Baseline (Mean ± SD, N = 79) Week 2 (Mean ± SD, N = 79) Week 4(Mean ± SD, N = 79) Week 8 (Mean ± SD, N = 79) Week 12 (Mean ± SD. N = 79)
Male n (%) 70 (89)
age 36.0 ± 11.5
HLA-B27 (%) 98.7
disease duration (months) 7.3 ± 8.0
NSAIDS (%) 82.3
Psoriasis (%) 0
Rheumatoid Arthritis (%) 0
Inflammatory Bowel Disease 0
BASDAI 5.4 ± 1.0 3.4 ± 1.5 2.2 ± 1.1 1.7 ± 1.0 1.4 ± 0.8
BASFI 3.2 ± 2.2 2.1 ± 1.8 1.4 ± 1.5 1.1 ± 1.2 0.9 ± 1.1
CRP 20.8 ± 32.2 3.8 ± 9.9 3.7 ± 10.0 3.1 ± 4.9 3.1 ± 4.2
ESR 28.3 ± 31.1 11.4 ± 19.7 8.4 ± 13.1 6.3 ± 6.8 6.5 ± 7.1
ASDAS 3.4 ± 0.8 1.8 ± 0.7 1.5 ± 0.7 1.2 ± 0.6 1.1 ± 0.7
  1. SD Standard deviation, BASDAI Bath Ankylosing Spondylitis Di, BASFI Bath Ankylosing Spondylitis Fu, ESR Erythrocyte sedimentation rate, CRP C reactive protein, ASDAS Ankylosing Spondylitis Disease NSADIS Non-steroidal anti-inflammator